SLIDE 1
World Leader in Alpha-pharmaceuticals A new class of drugs for cancer patients
Carnegie Healthcare Seminar March 2012 Andrew Kay, CEO
2012 Presentation 1203 v3
2
Disclaimer
THIS PRESENTATION AND ITS APPENDICES (HEREINAFTER JOINTLY REFERRED TO AS THE “PRESENTATION”) HAS BEEN PREPARED BY ALGETA ASA (THE “COMPANY”) EXCLUSIVELY FOR INFORMATION PURPOSES. THIS PRESENTATION HAS NOT BEEN REVIEWED BY, OR REGISTERED WITH, ANY PUBLIC AUTHORITY OR STOCK EXCHANGE. THE CONTENTS OF THIS PRESENTATION ARE NOT TO BE CONSTRUED AS LEGAL, BUSINESS, INVESTMENT OR TAX ADVICE. EACH RECIPIENT SHOULD CONSULT WITH ITS OWN LEGAL, BUSINESS, INVESTMENT AND TAX ADVISER AS TO LEGAL, BUSINESS, INVESTMENT AND TAX ADVICE. TO THE BEST KNOWLEDGE OF THE COMPANY, THE INFORMATION CONTAINED IN THIS PRESENTATION IS IN ALL MATERIAL RESPECTS IN ACCORDANCE WITH THE FACTS AS OF THE DATE HEREOF, AND CONTAINS NO MATERIAL OMISSIONS LIKELY TO AFFECT ITS IMPORT. HOWEVER, NO REPRESENTATION OR WARRANTY (EXPRESS OR IMPLIED) IS MADE AS TO, AND NO RELIANCE SHOULD BE PLACED ON, ANY INFORMATION, INCLUDING PROJECTIONS, ESTIMATES, TARGETS AND OPINIONS, CONTAINED HEREIN, AND NO LIABILITY WHATSOEVER IS ACCEPTED AS TO ANY ERRORS, OMISSIONS OR MISSTATEMENTS CONTAINED HEREIN, AND, ACCORDINGLY, NONE OF THE COMPANY OR ANY OF ITS SUBSIDIARY UNDERTAKINGS OR ANY SUCH PERSON’S DIRECTORS, OFFICERS OR EMPLOYEES ACCEPTS ANY LIABILITY WHATSOEVER ARISING DIRECTLY OR INDIRECTLY FROM THE USE OF THIS PRESENTATION. THERE MAY HAVE BEEN CHANGES IN MATTERS THAT AFFECT THE COMPANY SUBSEQUENT TO THE DATE OF THIS PRESENTATION. THE DELIVERY OF THIS PRESENTATION SHALL NOT UNDER ANY CIRCUMSTANCE CREATE ANY IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE DATE HEREOF OR THAT THE AFFAIRS OF THE COMPANY HAVE NOT SINCE CHANGED, AND THE COMPANY DOES NOT INTEND, AND DOES NOT ASSUME ANY OBLIGATION, TO UPDATE OR CORRECT ANY INFORMATION INCLUDED IN THIS PRESENTATION EXCEPT AS REQUIRED BY OSLO STOCK EXCHANGE RULES AND REGULATIONS OR APPLICABLE LAW. THIS PRESENTATION INCLUDES CERTAIN FORWARD-LOOKING INFORMATION AND STATEMENTS. SUCH FORWARD-LOOKING INFORMATION AND STATEMENTS ARE BASED ON THE CURRENT EXPECTATIONS, ESTIMATES AND PROJECTIONS OF THE COMPANY OR ASSUMPTIONS BASED ON THE INFORMATION AVAILABLE TO THE
- COMPANY. SUCH FORWARD-LOOKING INFORMATION AND STATEMENTS REFLECT CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS,
UNCERTAINTIES AND ASSUMPTIONS. THE COMPANY CANNOT GIVE ANY ASSURANCE TO THE CORRECTNESS OF SUCH INFORMATION AND STATEMENTS. THESE FORWARD-LOOKING INFORMATION AND STATEMENTS CAN BE IDENTIFIED BY THE FACT THAT THEY DO NOT RELATE ONLY TO HISTORICAL OR CURRENT FACTS. FORWARD-LOOKING STATEMENTS SOMETIMES USE WORDS SUCH AS "AIM", "ANTICIPATE", "EXPECT", "ESTIMATE", "PLAN", "MILESTONE", "BELIEVE", OR OTHER WORDS OF SIMILAR MEANING. EXAMPLES OF FORWARD-LOOKING STATEMENTS INCLUDE, AMONG OTHERS, STATEMENTS REGARDING OR WHICH MAKE ASSUMPTIONS IN RESPECT OF THE DEVELOPMENT OF ALPHARADIN AND ALGETA'S OTHER PRODUCTS, THE ONGOING EXPANSION OF THE ALPHARADIN PRODUCTION FACILITY AT IFE, THE QUANTITIES OF RADIUM-223 THAT THE IFE FACILITY WILL BE ABLE TO PRODUCE ONCE THE EXPANSION IS COMPLETED, THE ANTICIPATED MARKET DEMANDS FOR ALPHARADIN AND ALGETA'S OTHER PRODUCTS, THE RESULTS OF ONGOING CLINICAL TRIALS AND ALGETA'S STATED KEY ACTIVITIES AND MILESTONES FOR THE NEXT 12 MONTHS, INCLUDING REGULATORY FILINGS, AS WELL AS REGULATORY APPROVALS OF ALPHARADIN AND ALGETA'S OTHER PRODUCTS. BY THEIR NATURE, FORWARD-LOOKING INFORMATION AND STATEMENTS INVOLVE RISK AND UNCERTAINTY, AND SEVERAL FACTORS COULD CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS THAT MAY BE EXPRESSED OR IMPLIED BY THE FORWARD-LOOKING INFORMATION AND STATEMENTS IN THIS REPORT, INCLUDING, AMONG OTHERS, RISKS OR UNCERTAINTIES ASSOCIATED WITH THE SUCCESS OF FUTURE CLINICAL TRIALS, COLLABORATIONS WITH OTHER COMPANIES IN THE DEVELOPMENT OF TARGETING MOLECULES AND ALPHA PARTICLE PAYLOADS AND OTHER STRATEGIC TRANSACTIONS, THE IMPACT OF COMPETITION, OUR ABILITY TO PROTECT OUR INTELLECTUAL PROPERTY, OUR ABILITY TO SUCCESSFULLY COMMERCIALIZE ALPHARADIN AND OUR OTHER PRODUCTS, MANUFACTURING CAPACITY, THE POLICIES AND ACTIONS OF GOVERNMENTAL AND REGULATORY AUTHORITIES, CHANGES IN DOMESTIC AND FOREIGN LAWS AND REGULATIONS, CHANGES IN COMPETITION AND PRICING ENVIRONMENTS, FLUCTUATIONS IN CURRENCY EXCHANGE RATES AND INTEREST RATES AND OTHER FACTORS. SHOULD ONE OR MORE OF THESE RISKS OR UNCERTAINTIES MATERIALISE, OR SHOULD UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL RESULTS MAY VARY MATERIALLY FROM THOSE DESCRIBED IN THIS REPORT. ANY FORWARD-LOOKING INFORMATION OR STATEMENTS IN THIS REPORT SPEAK ONLY AS OF THE DATE THEY ARE MADE. EXCEPT AS REQUIRED BY THE OSLO STOCK EXCHANGE RULES OR APPLICABLE LAW, THE COMPANY DOES NOT INTEND, AND EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING, TO UPDATE OR CORRECT THE INFORMATION INCLUDED IN THIS REPORT, INCLUDING FORWARD- LOOKING INFORMATION AND STATEMENTS, TO REFLECT CHANGES IN THE COMPANY'S EXPECTATIONS WITH REGARD THERETO OR ANY CHANGES IN EVENTS, CONDITIONS OR CIRCUMSTANCES ON WHICH ANY STATEMENT IN THIS REPORT IS BASED.